Monoclonal Antibody Administration in an Academic Institution and Private Neurological Practice: A Tale of Two Clinics

Abstract

Background: The emergence of anti‐amyloid monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early‐stage Alzheimer’s disease (AD).

The paper